RBC Capital Sticks to Its Buy Rating for Teleflex (TFX)

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Teleflex (TFX – Research Report) on April 15 and set a price target of $265.00. The company’s shares closed yesterday at $210.10.

Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Boston Scientific, and Abbott Labs. According to TipRanks, Singh Chadha has an average return of -0.4% and a 42.05% success rate on recommended stocks.

Currently, the analyst consensus on Teleflex is a Moderate Buy with an average price target of $265.83.

TFX market cap is currently $9.91B and has a P/E ratio of 27.97.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teleflex (TFX) Company Description:

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. Teleflex was founded in 1943 and is headquartered in Wayne, PA.